Patents by Inventor Fubao Lin

Fubao Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES DERIVED FROM FIBRONECTIN WITH IMPROVED BIOACTIVITY AND REDUCED SUSCEPTIBILITY TO NEUTROPHIL ELASTASE DEGRADATION
    Publication number: 20230331814
    Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 19, 2023
    Inventors: Richard August Clark, Fubao Lin
  • Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
    Patent number: 11548935
    Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: January 10, 2023
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin
  • Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
    Patent number: 10729741
    Abstract: A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 4, 2020
    Assignee: NeoMatrix Therapeutics Inc.
    Inventors: Richard August Clark, Fubao Lin
  • Peptides Derived from Fibronectin with Improved Bioactivity and Reduced Susceptibility to Neutrophil Elastase Degradation
    Publication number: 20200223903
    Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.
    Type: Application
    Filed: October 12, 2017
    Publication date: July 16, 2020
    Inventors: Richard August Clark, Fubao Lin
  • Methods of Treating Burns with i.v. cP12 in a Window from 2 to 6 Hours After Injury
    Publication number: 20180271934
    Abstract: A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours.
    Type: Application
    Filed: March 27, 2017
    Publication date: September 27, 2018
    Inventors: Richard August Clark, Fubao Lin
  • Fibronectin polypeptides and methods of use
    Patent number: 8691944
    Abstract: Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: April 8, 2014
    Assignee: The Research Foundation for the State University of New York
    Inventors: Richard A. Clark, Xiang-Dong Ren, Fubao Lin
  • FIBRONECTIN POLYPEPTIDES AND METHODS OF USE
    Publication number: 20090111738
    Abstract: Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).
    Type: Application
    Filed: October 4, 2006
    Publication date: April 30, 2009
    Inventors: Richard A. Clark, Xiang-Dong Ren, Fubao Lin